1. Denmark Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Novozymes A/S

Novozymes A/S

NVZMF
Novozymes A/SUS flagOther OTC
57.50
USD
-0.21
- -
26.81BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.02
5.36
6.13
6.33
6.61
6.64
6.75
6.71
7.23
8.52
8.67
8.38
8.92
6.71
Basic EPS, GAAP
0.94
1.09
1.24
1.37
1.42
1.49
1.48
1.35
1.52
1.78
1.47
0.67
1.25
0.98
Free Cash Flow per Basic Share
0.78
1.65
1.04
1.24
1.12
1.08
1.1
1.71
1.45
0.6
1.02
1.49
1.74
0.88
Dividend per Share
0.3
0.34
0.4
0.48
0.54
0.61
0.68
0.71
0.71
0.74
1.38
0.55
0.86
1.13
Book Value per Share
4.65
4.67
4.83
4.97
5.22
5.32
5.35
5.67
5.74
6.61
6.93
24.38
24.22
24
Tangible Book Value per Share
3.5
3.58
3.9
4.03
4.02
4.29
4.48
4.16
3.47
4.62
4.76
2.52
-0.5
-0.47
Basic Weighted Avg Shares
314
312
306
300
295
290
285
280
278
277
277
458
466
467
Sales/Revenue/Turnover
1,574
1,673
1,876
1,903
1,952
1,927
1,924
1,883
2,010
2,356
2,402
3,834
4,158
3,134
Operating Margin (%)
24.7
25.26
27.74
27.9
28.31
28.28
24.66
25.76
25.98
25.23
25.43
17.19
21.23
21.73
Depreciation Expense
99
116
128
131
140
146
158
170
185
196
186
544
575
- -
Net Income, GAAP
295
339
378
410
419
432
422
380
423
493
406
306
584
459
Effective Tax Rate (%)
20.22
22.99
21.98
21.41
19.5
18.01
16.95
19.74
19.85
19.1
22.26
26.68
21.5
21.47
Profit Margin (%)
18.73
20.27
20.16
21.57
21.46
22.42
21.94
20.16
21.04
20.94
16.9
7.98
14.04
14.63
Working Capital
433
452
382
381
210
175
310
370
289
306
297
791
-758
823
LT Debt
227
162
161
231
175
197
432
488
543
524
612
1,530
- -
2,923
Total Equity
1,483
1,515
1,553
1,580
1,513
1,532
1,536
1,511
1,641
1,910
1,926
11,176
10,855
10,920
Return on Invested Capital (%)
18.67
18.4
22.97
23.13
23.97
23.05
19.46
19.15
18.37
17.9
16.31
6.05
5.78
7.51
Return on Capital (%)
18.95
20.31
22.77
24.42
23.52
22.62
21.78
18.95
18.97
19.06
14.52
4.53
5.26
6.36
Return on Common Equity (%)
21.99
23.27
25.79
27.63
27.61
28
27.5
24.38
26.56
28.82
21.65
4.68
5.2
8.18

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
303
- -
289
LT Borrowings
2,805
- -
2,923
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
466
466
466
Market Capitalization
178,614
186,479
173,310

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,983
2,046
Cash, Cash Equivalents & STI
- -
296
329
Accounts Receivable, Net
- -
716
756
Inventories
- -
772
793
Total Current Liabilities
- -
2,741
1,222
Payables & Accruals
- -
- -
- -
ST Debt
303
- -
289
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
50.07%
100.67%
-2.87%
Free Cash Flow
20.88%
31.04%
19.09%
Net Income, GAAP
7.79%
15.3%
90.84%
Sales/Revenue/Turnover
9.44%
18.79%
8.45%
Total Cash Common Dividend
16.66%
23.27%
61.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
854
978
981
- -
3,834
2025
1,078
1,018
- -
997
4,158
2026
1,119
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.06
0.19
- -
0.67
2025
0.4
0.29
- -
- -
1.25
2026
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.24
- -
- -
0.55
2025
- -
0.56
- -
- -
0.86
2026
0.57
- -
- -
- -
- -

Company Description

APIChat
CEO
Ester Baiget
Full Time Employees
10,582
Sector
Basic Materials
Industry
Chemicals - Specialty
Address
Krogshoejvej 36 Bagsvaerd Denmark 2880
IPO Date
Oct 15, 2010
CIK
0001131345
Website
novozymes.com
Similar Companies
RSXYZ Public Company Limited (XYZ.BK)
Allied Industrial Corp., Ltd. (4702.TWO)
Neogen Chemicals Limited (NEOGEN.BO)
Xinxiang Richful Lube Additive Co., Ltd (300910.SZ)
Leaf Resources Limited (LER.AX)
CHEMTRONICS.CO.,Ltd. (089010.KQ)
Business
Novozymes A/S is a biotechnology company that develops, manufactures and sells industrial enzymes, microorganisms, functional proteins and biopharmaceutical ingredients for applications including household care such as laundry, dishwashing and cleaning solutions; food and beverages encompassing baking, dairy, beverages and protein ingredients; agriculture with crop protection, animal health, nutrition, grain and technical processing solutions; bioenergy featuring fermentation, lignocellulosic hydrolysis, liquefaction and saccharification; human health including lipases, proteases and trypsin for biocatalysis and cell culture; and planetary health biosolutions like fiber modification, bleach boosting and biogas. The company, founded in 2000 as a spin-off from Novo Nordisk with roots tracing to 1925, was headquartered in Bagsværd, Denmark, and operated globally across Europe, North America, Asia Pacific, Latin America, the Middle East and Africa, serving customers in over 130 markets through facilities in countries including the United States, China, India and Brazil. In January 2024, Novozymes completed a statutory merger with Chr. Hansen Holding A/S to form Novonesis A/S, creating a leading global biosolutions partner with complementary portfolios in enzymes, microbes and probiotics, projected annual revenues exceeding EUR 3.5 billion, and expected synergies of EUR 200 million; post-merger, Novonesis reported 8% organic sales growth and an adjusted EBITDA margin of 36.1% for 2024, launched 45 new innovations with 30% of sales from products introduced in the prior five years, and narrowed its 2025 outlook to 6-8% organic growth and 37-38% EBITDA margin.

Company News

APIChat

  • defenseworld.net

    Novozymes A/S (OTCMKTS:NVZMF) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened

  • seekingalpha.com

    Novonesis A/S (NVZMF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Novonesis A/S (NVZMF) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    Novonesis A/S (NVZMF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Novonesis A/S (NVZMF) Q3 2024 Earnings Call Transcript